TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1847026
Drug: Placebo (subcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous, daily for 6 months)
Study: 6340974
Drug: Trimethoprim (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (250 mg)/sulfamethopyrazine (200 mg) combination given once daily after a double loading dose on the first day.
Study: 6340974
Drug: Ampicillin 500
Normalized name: ampicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 500 mg 4-times daily.
Study: 31655882
Drug: Glove-finger pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glove-finger pack soaked with saline solution
Study: 27377131
Drug: Traditional occupational
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional occupational therapy intervention sessions targeting VMI skills
Study: 22811376
Drug: MVit (VitC:
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVit (VitC: 200 mg; VitE: 400 IU; VitB6: 25 mg; Folic Acid: 400 ug; VitB12: 400 ug)
Study: 22811376
Drug: MVit +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVit + N3 (2 g N3, 760 mg EPA, 440 mg DHA)
Study: 22811376
Drug: N3 (2
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N3 (2 g N3, 760 mg EPA, 440 mg DHA)
Study: 19056661
Drug: Anti-H. pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-H. pylori treatment with amoxicillin (1 g twice daily) and omeprazole (20 mg twice daily)
Study: 17908276
Drug: Concentration-controlled MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentration-controlled MMF dosing
Study: 17908276
Drug: Fixed-dose MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose MMF
Study: 11751658
Drug: Metoprolol CR/XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/XL 12.5 mg once daily
Study: 11751658
Drug: Metoprolol CR/XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/XL titrated to 200 mg once daily
Study: 10739391
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at 5 ppm
Study: 8116033
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous immunoglobulin (IVIG; 0.5 g/kg) for 6 doses and oral acyclovir for 3 months
Study: 8116033
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (2.5 mg/kg) twice daily for 2 weeks followed by oral acyclovir for 3 months
Study: 8116033
Drug: Cytogam (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytogam (100-150 mg/kg) plus 2 weeks of i.v. ganciclovir followed by 3 months of oral acyclovir
Study: 8116033
Drug: Standard IVIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard IVIG (5 doses over 2 months)
Study: 30286025
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy for patients with locally advanced disease
Study: 30286025
Drug: Nonoperative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative management in the context of the Organ Preservation in Rectal Adenocarcinoma trial
Study: 21979399
Drug: Diabetic colon
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic colon preparation (10 ounces of magnesium citrate 2 days prior, followed by 10 ounces of magnesium citrate and 4-L polyethylene glycol the day prior)
Study: 21979399
Drug: Standard colon
Normalized name: COLON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard colon preparation (10 ounces of magnesium citrate and 4-L polyethylene glycol the day prior)
Study: 27813503
Drug: Naproxen sodium,
Normalized name: Naproxen Sodium, sodium compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen sodium, paracetamol and pamabrom
Study: 27813503
Drug: Paracetamol, pyrilamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol, pyrilamine and pamabrom
Study: 23633128
Drug: D-mannose powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-mannose powder (2 g in 200 ml of water daily for 6 months)
Study: 23633128
Drug: Nitrofurantoin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin (50 mg daily)
Study: 18619113
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 g/kg dose)
Study: 15984978
Drug: VSL#3, 3,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSL#3, 3,600 billion bacteria daily in two divided doses for 6 weeks
Study: 8821078
Drug: L-Dopa medication
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Dopa medication
Study: 8821078
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of L-Dopa
Study: 31454432
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with interval debulking
Study: 24490769
Drug: First generation
Normalized name: First generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: First generation drug-eluting stents
Study: 24490769
Drug: Latest generation
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latest generation drug-eluting stents
Study: 20451404
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) 75 mg/m² subcutaneously for 7 days every 28 days (n=38)
Study: 9040303
Drug: Famciclovir 250
Normalized name: famciclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 250 mg twice daily
Study: 10193975
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients with a positive history of oral herpes labialis)
Study: 2271467
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (subclavian perivascular injection after withdrawing from the artery)
Study: 2271467
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (subclavian perivascular injection after advancing through the artery)
Study: 7270401
Drug: Intravenous prenalterol
Normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prenalterol (PNL) 75 to 225 microgram/kg
Study: 7270401
Drug: Intravenous prenalterol
Normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prenalterol (PNL) during exercise
Study: 7270401
Drug: Oral prenalterol
Normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prenalterol (PNL) 30 to 200 mg/day
Study: 7270401
Drug: Oral prenalterol
Normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prenalterol (PNL) vs placebo
Study: 24231843
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of epirubicin and interferon-α2b
Study: 17154642
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (1 mg/day)
Study: 12897376
Drug: Fasting insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fasting insulin measurement
Study: 9183341
Drug: Post-glucose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-glucose insulin measurement
Study: 29778331
Drug: Goal-directed perfusion
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed perfusion (GDP) strategy during cardiopulmonary bypass (CPB) aimed to maintain oxygen delivery (DO2) at ≥280 mL·min‐1·m‐2
Study: 27260150
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg on day 1, 75 mg on days 2 and 3)
Study: 25471907
Drug: Topical intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intra-articular TXA (3 g of TXA in 100 mL of physiological saline solution)
Study: 25471907
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (15 mg/kg in 100 mL of physiological saline solution, one dose before tourniquet release and another three hours after surgery)
Study: 25471907
Drug: Topical intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intra-articular TXA
Study: 21999138
Drug: 5 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 weekly two-needle arthrocenteses plus low molecular weight HA (E)
Study: 21999138
Drug: 5 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 weekly single-needle arthrocenteses plus low molecular weight HA (F)
Study: 18388888
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and exercise (treatment group)
Study: 15538395
Drug: Alprostadil transdermal
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil transdermal cream (approximately 100 mg containing 300 microg alprostadil) administered by self-insertion into the glans meatus.
Study: 15538395
Drug: Alprostadil transdermal
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil transdermal cream (approximately 100 mg containing 300 microg alprostadil) administered dropwise into the metal opening without touching the penis.
Study: 12874157
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Chlorella-derived dietary supplement
Study: 12874157
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg Chlorella-derived dietary supplement
Study: 10563544
Drug: Nicotine solution
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine solution (1.2 mg, pH 4.5)
Study: 1681215
Drug: Ocular tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ocular tetracycline treatment
Study: 6496995
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (5.0 mg)
Study: 6496995
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.05-0.07 mg/kg)
Study: 6496995
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine and Intravenous morphine
Study: 24487957
Drug: High-intensity laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity laser therapy (HILT) + exercise
Study: 24487957
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) + exercise
Study: 22065170
Drug: Tovaxin (autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tovaxin (autologous T-cell immunotherapy)
Study: 12850395
Drug: lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lercanidipine 10 to 20 mg
Study: 12850395
Drug: nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine GITS 30 to 60 mg
Study: 10593371
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg of ganirelix administered subcutaneously
Study: 10593371
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg of ganirelix administered intravenously
Study: 6809161
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine chewing-gum
Study: 6809161
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mg nicotine, unbuffered)
Study: 28931384
Drug: Internet-based tool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based tool for parents (monthly emails with links to an age-appropriate website)
Study: 26037730
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list group (no acupuncture treatment)
Study: 23833851
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg) added to bupivacaine (0.5%) - fentanyl (50 microg)
Study: 19961932
Drug: Proguanil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil with efavirenz (400mg daily for 11 days)
Study: 19213336
Drug: Kuntai Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuntai Capsule (KTC) 4 capsules twice a day for 1 year
Study: 19213336
Drug: Premarin 0.45
Normalized name: Premarin 0.45mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin 0.45 mg per day (with 2 mg medroxyprogesterone for Ue) for 1 year
Study: 19213336
Drug: Kuntai Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuntai Capsule (KTC)
Study: 10812283
Drug: Daily buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily buprenorphine administration (8 mg)
Study: 10812283
Drug: Thrice-weekly buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly buprenorphine administration (16 mg on Mondays and Wednesdays, 24 mg on Fridays)
Study: 6809024
Drug: Pirprofen 200
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pirprofen 200 mg 8 hourly
Study: 29384321
Drug: Astaxanthin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin (8 mg once daily for 8 weeks)
Study: 26922656
Drug: AZD8529 40
Normalized name: AZD8529
DrugBank: AZD8529 (DB16073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8529 40 mg
Study: 21076372
Drug: Valganciclovir prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir prophylaxis (900 mg once daily for 200 days)
Study: 21076372
Drug: Valganciclovir prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir prophylaxis (900 mg once daily for 100 days)
Study: 16120821
Drug: 32 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg/d candesartan
Study: 19211712
Drug: 64 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 mg/d candesartan
Study: 11865366
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous antithrombin III
Study: 10599402
Drug: Normovolemic haemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normovolemic haemodilution with crystalloid solutions until a hematocrit value of 21%
Study: 492050
Drug: Metoprolol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (0.2 mg/kg)
Study: 27697423
Drug: Sticker prompts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sticker prompts affixed to refuse bins in treatment group
Study: 21359979
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine injection (1/100,000) in the control group
Study: 21359979
Drug: No epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No epinephrine injection in the intervention group
Study: 18232619
Drug: Self-efficacy for
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-efficacy for Appropriate Medication Use Scale (SEAMS)
Study: 15533488
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet (15% fat or less) with supplements (vitamin E and selenium)
Study: 15533488
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet (15% fat or less) without supplements
Study: 15533488
Drug: Supplements alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplements alone (vitamin E and selenium)
Study: 9659838
Drug: E +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + C (ephedrine 20 mg and caffeine 200 mg)
Study: 8719299
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy for 3 months
Study: 8719299
Drug: GHRH combined
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH combined with pyridostigmine (PD, 120 mg po)
Study: 8719299
Drug: PD administration
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD administration
Study: 31279972
Drug: PVI +
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PVI + VOM ethanol infusion
Study: 28410341
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg every 4 weeks up to 7 years
Study: 22350036
Drug: Xanthan-based 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthan-based 1.5% chlorhexidine (CHX) gel (Xan-CHX)
Study: 19116968
Drug: Disodium EDTA
Normalized name: Disodium EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium EDTA administration through single needle mesotherapy and 15 minutes of pulsed-mode 1 MHz-ultrasound
Study: 19116968
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no disodium EDTA treatment)
Study: 19116968
Drug: Disodium EDTA
Normalized name: Disodium EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium EDTA administration
Study: 12692182
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (500 mg day-1 for 8 weeks)
Study: 2058825
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol and alfentanil (ED95)
Study: 2058825
Drug: Meperidine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (25 mg i.v.) given to 5 patients from K1
Study: 4082090
Drug: Aspirin 50
Normalized name: aspirin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 50 mg/day
Study: 4082090
Drug: Aspirin 324
Normalized name: aspirin 324 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 324 mg/day
Study: 30500136
Drug: Plant-based hypoallergenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant-based hypoallergenic ointment (Doctor Rogers RESTORE® Healing Balm)
Study: 30500136
Drug: Petroleum-based lanolin-containing
Normalized name: lanolin / petrolatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petroleum-based lanolin-containing ointment (Aquaphor® Healing Ointment)
Study: 25850997
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg once daily
Study: 15773645
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of local anaesthetic and steroid
Study: 12913719
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg selenium daily orally for 1 month
Study: 10498759
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) capsules (2 g b.d.; containing 1.4 g eicosapentaenoic acid and 1.0 g docosahexaenoic acid per day)
Study: 10498759
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil capsules (2 g b.d.; placebo group)
Study: 10498759
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplements (self-reported use)
Study: 8604261
Drug: Bupivacaine-norepinephrine topical
Normalized name: mepivacaine / norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-norepinephrine topical solution (Bupivanor)
Study: 8604261
Drug: Topical tetracaine-adrenaline-cocaine
Normalized name: adrenalone / tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracaine-adrenaline-cocaine (TAC)
Study: 15050319
Drug: Hyperfractionated accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated accelerated radiochemotherapy (to 70.6 Gy) with concurrent mitomycin C and 5-fluorouracil
Study: 15050319
Drug: Hyperfractionated accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated accelerated radiotherapy (RT) alone (to a total radiation dose of 77.6 Gy)
Study: 15448032
Drug: Bevacizumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (3 or 10 mg/kg every 2 weeks)
Study: 15448032
Drug: Bevacizumab (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (higher dose)
Study: 15448032
Drug: Bevacizumab (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (long-term therapy)
Study: 8557014
Drug: alfentanil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 20 micrograms kg‐1 and propofol 2.0‐2.5 mg kg‐1
Study: 8557014
Drug: fentanyl 3
Normalized name: FENTANYL 37.5MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl 3 micrograms kg‐1 and thiopentone 4‐6 mg kg‐1
Study: 1660414
Drug: Methylprednisolone treatment
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone treatment in steroid‐treated control group (n = 10)
Study: 6627819
Drug: metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (100 to 400 mg/day) with prazosin (2 to 4 mg/day)
Study: 6627819
Drug: labetalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol (200 to 1000 mg/day)
Study: 31728883
Drug: Hypofractionated radiotherapy
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiotherapy of 39 Gy in 13 fractions over 2.6 weeks with concurrent Temozolomide (TMZ) 75 mg/m2 from day 1 to day 17 followed by adjuvant TMZ for six cycles.
Study: 22770926
Drug: Silymarin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (three 140‐mg tablets daily for 3 months)
Study: 22770926
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 tablets daily for 3 months)
Study: 20398339
Drug: Intramuscular artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular artesunate (2.4 mg/kg immediately followed by 1.2 mg/kg at 12 hours then 24 hours then daily)